In December 2004, the US FDA approved pegaptanib for the treatment of all types of AMD.2 As we all know, tumour blood vessels play an important role in tumour growth, providing essential oxygen and nutrients for tumour metabolism and metastasis.6, 7 VEGF is a very important regulator of endothelial cell growth and survival.8 So inhibiting VEGF may be a viable way to treat cancer.9, 10 Therefore, pegaptanib might be a promising candidate for VEGF‐targeting drugs for cancer therapy. The gene discussed is VEGFA; the disease is age-related macular degeneration.